A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY
2 other identifiers
interventional
263
3 countries
38
Brief Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 obesity
Started Dec 2024
38 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 2, 2024
CompletedFirst Posted
Study publicly available on registry
December 5, 2024
CompletedStudy Start
First participant enrolled
December 9, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 23, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 12, 2026
CompletedFebruary 6, 2026
February 1, 2026
11 months
December 2, 2024
February 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percent change from baseline in body weight
Baseline to Week 16
Secondary Outcomes (1)
Number of participants with treatment emergent adverse events
From first dose (Day 1) up to 28-35 days after final dose, a total of approximately 21 weeks
Study Arms (4)
PF-07976016 Dose 1
EXPERIMENTALPF-07976016 Dose 2
EXPERIMENTALPF-07976016 Dose 3
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1
- Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1
- Eligible and willing to receive required background medicine
- Willing and able to comply with all study procedures
You may not qualify if:
- Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes.
- Use of any prohibited prior or concomitant medication(s)
- Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (38)
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
Artemis Institute for Clinical Research
San Diego, California, 92103, United States
Clinical & Translational Research Center
Aurora, Colorado, 80045, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Westside Center for Clinical Research
Jacksonville, Florida, 32205, United States
New Horizon Research Center
Miami, Florida, 33165, United States
Renstar Medical Research
Ocala, Florida, 34470, United States
Renstar Medical Research
Ocala, Florida, 34471, United States
St Johns Center for Clinical Research
Saint Augustine, Florida, 32086, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291, United States
East-West Medical Research Institute
Honolulu, Hawaii, 96814, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606, United States
L-MARC Research Center
Louisville, Kentucky, 40213, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
StudyMetrix Research
City of Saint Peters, Missouri, 63303, United States
Rochester Clinical Research, LLC
Rochester, New York, 14609, United States
Accellacare - Wilmington
Wilmington, North Carolina, 28401, United States
AMR Clinical
Norman, Oklahoma, 73069, United States
Cornerstone Nutrition and Diabetes
Norman, Oklahoma, 73069, United States
Capital Area Research, LLC
Camp Hill, Pennsylvania, 17011, United States
Elligo Clinical Research Center
Austin, Texas, 78704, United States
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, 78749, United States
Velocity Clinical Research, Dallas
Dallas, Texas, 75230, United States
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Consano Clinical Research, LLC
Shavano Park, Texas, 78231, United States
Chrysalis Clinical Research
St. George, Utah, 84790, United States
Southwest Internal Medicine, PC
St. George, Utah, 84790, United States
Selma Medical Associates
Winchester, Virginia, 22601, United States
Ocean West Research Clinic
Surrey, British Columbia, V3Z 2N6, Canada
Dawson Clinical Research Inc.
Guelph, Ontario, N1H 1B1, Canada
The Wharton Medical Clinic Clinical Trials Inc.
Hamilton, Ontario, L8L 5G8, Canada
Milestone Research Inc.
London, Ontario, N5W 6A2, Canada
Canadian Phase Onward
Toronto, Ontario, M3J 0K2, Canada
Centrum Zdrowia Metabolicznego Pawel Bogdanski
Poznan, Greater Poland Voivodeship, 60-589, Poland
Medicome Sp. z o. o.
Oświęcim, Lesser Poland Voivodeship, 32-600, Poland
Ekamed
Lublin, Lublin Voivodeship, 20-718, Poland
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Pomeranian Voivodeship, 80-546, Poland
Centrum Medyczne Pratia Gdynia
Gdynia, Pomeranian Voivodeship, 81-338, Poland
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 2, 2024
First Posted
December 5, 2024
Study Start
December 9, 2024
Primary Completion
October 23, 2025
Study Completion
January 12, 2026
Last Updated
February 6, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.